The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9% during the forecast period. Growth in the glycated albumin assay market is mainly driven by factors such as the rising prevalence of diabetes and increasing government focus on disease diagnosis.
The major players in glycated albumin assay market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), and Hzymes Biotech (China). The market players are focusing on the research of the glycated albumin assays and including new products in the market.
Comments